Melola Discovery

← Melola Discovery

Open access Journal SINTA 1

In silico molecular docking investigation of Morus L. bioactive compounds as potential SIRT1 activators for endothelial anti-aging therapy

Heart Science Journal · Vol. 7 No. 1 (2026) · pp. 46–52

DOI
10.21776/ub.hsj.2026.007.01.8
ISSN
2721-9984, 2721-9976
Published
2026-01-31
Publisher
Universitas Brawijaya
Language
en
License
creativecommons.org/licenses/by/4.0

Abstract

Background: The silent progression of vascular aging, characterized by endothelial dysfunction, has been closely linked to a decline in SIRT1 activity. Natural polyphenols have drawn increasing attention as potential modulators of this longevity-associated enzyme, offering therapeutic promise through antioxidant and anti-inflammatory effects. Objective: This study aimed to conduct an in silico analysis of natural SIRT1 activators, compare their interactions with simvastatin, and explore their structure-activity relationships to identify potential candidates for vascular-protective nutraceuticals or therapeutic adjuvants. Methods: Molecular docking was performed using PyRx 8.0 to assess ligand-SIRT1 interactions. Pharmacokinetic properties were evaluated through Lipinski’s Rule of Five and Veber’s Rule using SwissADME, while toxicity predicted with ProTox-II. Ligand-receptor interactions were visualized using LigPlot+. Result: Moracin demonstrated the strongest binding affinity to SIRT1 (–11.3 kcal/mol), followed by resveratrol (–9.6 kcal/mol), chlorogenic acid (–9.5 kcal/mol), and quercetin (–8.9 kcal/mol), all outperforming simvastatin (–8.4 kcal/mol). Moracin, resveratrol, and quercetin satisfied key drug-likeness criteria, while chlorogenic acid showed limitations in permeability. Toxicity profiling positioned resveratrol as the safest compound (GHS class 6), with moracin and quercetin also showing favorable profiles. Simvastatin exhibited broader toxicity risks. Conclusion: In silico and molecular docking results presented evidence for the potential of Morus L. polyphenols, especially moracin and resveratrol, as SIRT1 activators for endothelial anti-aging therapy. However, these findings remain predictive and require further validation through in vitro and in vivo studies to confirm the therapeutic efficacy and safety of these compounds as anti-aging agents.

Keywords

Collaboration network of the authors

40 authors · 275 co-authorship links · 4 across different organisations · showing the 40 most connected

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • University of Brawijaya
  • National Research and Innovation Agency
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Anna Fuji RahimahUniversity of Brawijaya18
Cholid Tri TjahjonoUniversity of Brawijaya18
Ardian RizalUniversity of Brawijaya18
Budi SatrijoUniversity of Brawijaya17
Indra PrasetyaUniversity of Brawijaya17
Setyasih AnjarwaniUniversity of Brawijaya16
Novi KurnianingsihUniversity of Brawijaya13
Yoga WaranugrahaUniversity of Brawijaya10
Djanggan SargowoUniversity of Brawijaya9
Sasmojo WiditoUniversity of Brawijaya9
Heny MartiniUniversity of Brawijaya9
Adhika Prastya WikanandaUniversity of Brawijaya4
Tri AstiawatiUniversity of Brawijaya4
Putri Annisa KamilaUniversity of Brawijaya3
Dadang HendrawanUniversity of Brawijaya3
Muhammad Rizki FadlanUniversity of Brawijaya3
Fandy HazzyUniversity of Brawijaya3
Wella KarolinaUniversity of Brawijaya3
Hayla Iqda MillisaniUniversity of Brawijaya3
Veny KurniawatiUniversity of Brawijaya2
Tonny AdriyantoUniversity of Brawijaya2
Jonny Karunia FajarUniversity of Brawijaya2
Olivia HandayaniUniversity of Brawijaya2
Fahmy RusnantaUniversity of Brawijaya2
Fitranti Suciati LaitupaUniversity of Brawijaya2
Oktafin Srywati PamunaUniversity of Brawijaya2
Anna Fuji RahimahAffiliation unknown2
Imelda KrisnasariUniversity of Brawijaya2
Ratna PancasariUniversity of Brawijaya2
Ayu Asri Devi AdityawatiUniversity of Brawijaya2
Krishna Ari NugrahaUniversity of Brawijaya2
Seprian WidasmaraUniversity of Brawijaya2
Pawik SupriadiUniversity of Brawijaya2
Wira KimahesaUniversity of Brawijaya2
Valerinna YogibuanaAffiliation unknown2

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OAI-PMH (metadata jurnal) https://heartscience.ub.ac.id/index.php/heartscience/oai, first harvested 8 Nov 2026, last seen 16 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">In silico molecular docking investigation of Morus L. bioactive compounds as potential SIRT1 activators for endothelial anti-aging therapy</dc:title>
	<dc:creator xml:lang="en">Rahma, Oktivani Adelathifa</dc:creator>
	<dc:creator xml:lang="en">Rohman, Mohammad Saifur</dc:creator>
	<dc:creator xml:lang="en">Akbar, Naufal Zulfikar </dc:creator>
	<dc:creator xml:lang="en">Rohman, Ibrahim Abdur</dc:creator>
	<dc:creator xml:lang="en">Nurwidyaningtyas, Wiwit</dc:creator>
	<dc:subject xml:lang="en">Chlorogenic Acid (CGA)</dc:subject>
	<dc:subject xml:lang="en">Endothelial dysfunction</dc:subject>
	<dc:subject xml:lang="en">in silico</dc:subject>
	<dc:subject xml:lang="en">moracin</dc:subject>
	<dc:subject xml:lang="en">quercetin</dc:subject>
	<dc:subject xml:lang="en">resveratrol</dc:subject>
	<dc:subject xml:lang="en">SIRT1</dc:subject>
	<dc:description xml:lang="en">Background: The silent progression of vascular aging, characterized by endothelial dysfunction, has been closely linked to a decline in SIRT1 activity. Natural polyphenols have drawn increasing attention as potential modulators of this longevity-associated enzyme, offering therapeutic promise through antioxidant and anti-inflammatory effects.
Objective: This study aimed to conduct an in silico analysis of natural SIRT1 activators, compare their interactions with simvastatin, and explore their structure-activity relationships to identify potential candidates for vascular-protective nutraceuticals or therapeutic adjuvants.
Methods: Molecular docking was performed using PyRx 8.0 to assess ligand-SIRT1 interactions. Pharmacokinetic properties were evaluated through Lipinski’s Rule of Five and Veber’s Rule using SwissADME, while toxicity predicted with ProTox-II. Ligand-receptor interactions were visualized using LigPlot+.
Result: Moracin demonstrated the strongest binding affinity to SIRT1 (–11.3 kcal/mol), followed by resveratrol (–9.6 kcal/mol), chlorogenic acid (–9.5 kcal/mol), and quercetin (–8.9 kcal/mol), all outperforming simvastatin (–8.4 kcal/mol). Moracin, resveratrol, and quercetin satisfied key drug-likeness criteria, while chlorogenic acid showed limitations in permeability. Toxicity profiling positioned resveratrol as the safest compound (GHS class 6), with moracin and quercetin also showing favorable profiles. Simvastatin exhibited broader toxicity risks.
Conclusion: In silico and molecular docking results presented evidence for the potential of Morus L. polyphenols, especially moracin and resveratrol, as SIRT1 activators for endothelial anti-aging therapy. However, these findings remain predictive and require further validation through in vitro and in vivo studies to confirm the therapeutic efficacy and safety of these compounds as anti-aging agents.</dc:description>
	<dc:publisher xml:lang="en">Universitas Brawijaya</dc:publisher>
	<dc:date>2026-01-31</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://heartscience.ub.ac.id/index.php/heartscience/article/view/20425</dc:identifier>
	<dc:identifier>10.21776/ub.hsj.2026.007.01.8</dc:identifier>
	<dc:source xml:lang="en">Heart Science Journal; Vol. 7 No. 1 (2026): Accelerating Clinical Breakthroughs: The Journey from Molecular Discovery to Patient Care; 46-52</dc:source>
	<dc:source>2721-9984</dc:source>
	<dc:source>2721-9976</dc:source>
	<dc:source>10.21776/ub.hsj.2026.007.01</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://heartscience.ub.ac.id/index.php/heartscience/article/view/20425/556</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2026 Oktivani Adelathifa Rahma, Mohammad Saifur Rohman, Naufal Zulfikar Akbar, Ibrahim Abdur Rohman, Wiwit Nurwidyaningtyas</dc:rights>
	<dc:rights xml:lang="en">http://creativecommons.org/licenses/by/4.0</dc:rights>
</oai_dc:dc>